newsfilter
← Latest News
GlobeNewswire·

FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results

Announced sale of FibroGen China to AstraZeneca for a total consideration of approximately $160 million Transaction expected to close by mid-2025 Upon close of sale of FibroGen China, cash runway extended into 2027